FILTER
FILTERED INTERVIEW RESULTS
Katrin Rupalla
CEO, YMMUNOBIO
"Based on our in vivo data for our lead CEACAM1/5 antibody YB-200 we have obtained orphan drug status from FDA for the treatment of liver cancer."
Roger Erickson
CEO AND FOUNDER, INTERBIOME
"We want to pioneer a commodity utility approach for needed areas of pharmaceutical manufacturing, and make that available as a sustainable platform that any country can start with and innovate from."
Jan Kengelbach
CEO, AENOVA GROUP
"Experienced CDMOs can provide companies with access to new formulation and technology methods that improve the bioavailability of difficult-to-formulate compounds."
Donna LaVoie
PRESIDENT AND CEO, LAVOIEHEALTHSCIENCE
"Companies should be ready to address hostile short-selling and unsolicited takeover bids, develop rapid responses to special meetings and activist demands, and vigorously engage with institutional shareholders, proxy advisory firms, and potential regulators."
Daniel Prince
CEO, PRINCE STERILIZATION SERVICES
"The expansion will allow Prince to more than double its headcount, increase manufacturing capacity, and offer additional ready-to-use products and sterilization services to the market."
Jason Latkowcer
PRESIDENT, CEO AND DIRECTOR, PAN AMERICAN ENERGY CORP.
"Proving commercially viable lithium mineralization has the potential for tremendous value generation for investors."
Tom Sellig
CEO, ADARE PHARMA SOLUTIONS
"For every challenge, we have a set of tools we can leverage to create optimized solutions beyond taste masking."
Louis Kassa
PRESIDENT AND CEO, PENNSYLVANIA BIOTECHNOLOGY CENTER (PABC)
"I hope to continue seeing companies coming from across the country contributing to the significant growth of the greater Philadelphia area in life sciences."
Raphael Carmona
VICE PRESIDENT, SALES AREA NORTH AMERICA - SANDVIK ROCK PROCESSING SOLUTIONS, SANDVIK
"When it comes to technology, we want a single software platform gathering all data from the crushers, so the customer to be able to monitor all of them in a centralized space."
Ron White
PRESIDENT, 3D-P
"Applications for productivity, efficiency, safety, and sustainability increase all require a strong network."
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENTLY PUBLISHED
United States Life Sciences 2023
In many ways, 2022 was a turning point for the US life sciences industry. After having provided a lightning-quick response to the Covid-19 pandemic, the industry gathered the lessons learned and sought a sense of normalcy to continue developing necessary drugs for patients worldwide. Yet, the geopolitical, macroeconomic, and regulatory environments all come with their set of challenges, forcing executives into increasingly complex decisions when defining their strategies.
In many ways, 2022 was a turning point for the US life sciences industry. After having provided a lightning-quick response to the Covid-19 pandemic, the industry gathered the lessons learned and sought a sense of normalcy to continue developing necessary drugs for patients worldwide. Yet, the geopolitical, macroeconomic, and regulatory environments all come with their set of challenges, forcing executives into increasingly complex decisions when defining their strategies.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
